Skip to main content
CBT
NYSE Industrial Applications And Services

Cabot Q3 Adjusted EPS of $1.67 Beats Consensus; FY26 Guidance Tightened to $6.15–$6.45

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Chemical Stocks · Materials
Sentiment info
Neutral
Importance info
7
Price
$79.83
Mkt Cap
$4.121B
52W Low
$58.33
52W High
$94.53
52W Position info
37% above low
Off High info
16% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CBT sits 37% above its 52-week low of $58.33.

Summary

Cabot Corporation reported fiscal Q3 2026 adjusted EPS of $1.67, beating estimates, and tightened its full-year adjusted EPS guidance to $6.15–$6.45. Revenue rose 6% to $982 million, driven by Performance Chemicals strength, while Reinforcement Materials EBIT fell 24% on lower pricing.


Key Events · Earnings and Guidance · CBT

  • Q3 Adjusted EPS Beats Consensus

    Adjusted EPS of $1.67 exceeded the $1.66 consensus estimate, with revenue up 6% year-over-year to $982 million. GAAP EPS was $0.12, weighed down by $1.55 per share in restructuring and pension termination charges.

  • FY26 Guidance Tightened

    Management narrowed the full-year adjusted EPS outlook to $6.15–$6.45 from the prior $6.00–$6.50 range, implying a Q4 adjusted EPS of approximately $1.33–$1.63 based on year-to-date adjusted EPS of $4.82.

  • Segment Performance Diverges

    Performance Chemicals EBIT rose 19% to $68 million on higher volumes and margins, while Reinforcement Materials EBIT fell 24% to $97 million due to lower gross profit per ton from 2026 customer agreements, partially offset by 5% volume growth.

  • Restructuring Charges Impact GAAP Results

    Pre-tax certain items of $78 million included $42 million for global restructuring (plant closures in Argentina and the Netherlands) and $30 million for an employee benefit plan settlement, resulting in a $1.55 per share after-tax charge.


Analysis · CBT · Industrial Applications And Services

Cabot delivered a solid quarter with adjusted EPS of $1.67, edging past the $1.66 consensus, and revenue up 6% to $982 million. Performance Chemicals drove the beat with 19% EBIT growth, while Reinforcement Materials saw a 24% EBIT decline on lower pricing. The company tightened its full-year adjusted EPS guidance to $6.15–$6.45, signaling confidence in the final quarter. However, GAAP EPS was just $0.12 due to $1.55 per share in restructuring charges tied to plant closures and a pension plan termination — non-cash items that don't affect the operating story. With $1.3 billion in liquidity and a net debt ratio of 1.4x, the balance sheet remains strong. The upcoming CEO transition on October 1 adds a layer of management change, but the reaffirmed battery materials EBITDA target of ~$40 million shows growth initiatives are on track.

At the time of this filing, CBT was trading at $79.83 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $58.33 to $94.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CBT - Latest Insights

CBT
Aug 03, 2026, 4:52 PM EDT
Source: Reuters
Importance Score:
7
CBT
Aug 03, 2026, 4:36 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
CBT
Jul 30, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
CBT
May 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
CBT
May 06, 2026, 4:23 PM EDT
Filing Type: 10-Q
Importance Score:
8